SANTA CLARA, Calif., Dec. 01, 2016 -- Applied Materials, Inc. today announced that its Board of Directors has approved a quarterly cash dividend of $0.10 per share payable on the company’s common stock. The dividend is payable on March 15, 2017 to shareholders of record as of February 22, 2017.
About Applied Materials
Applied Materials, Inc. (Nasdaq:AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible the technology shaping the future. Learn more at www.appliedmaterials.com.
Contact: Kevin Winston (editorial/media) 408.235.4498 Michael Sullivan (financial community) 408.986.7977


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Italy Fines Apple €98.6 Million Over App Store Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



